Advertisement


Scott Kopetz, MD, on Colorectal Cancer: Results of the SWOG 1406 Trial

2017 Gastrointestinal Cancers Symposium

Advertisement

Scott Kopetz, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (Abstract 520).



Related Videos

Pancreatic Cancer
Hepatobiliary Cancer

Eileen M. O’Reilly, MD, on Pancreatic and Hepatobiliary Cancers: Selecting High-Impact Targets

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.

Hepatobiliary Cancer

Ignacio Melero, MD, PhD, on Hepatocellular Carcinoma: Results of the CheckMate 040 Trial

Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).

Pancreatic Cancer

Sarah E. Hoffe, MD, on Pancreatic Cancer and SBRT: Pros and Cons

Sarah E. Hoffe, MD, of the Moffitt Cancer Center, discusses the controversial role of radiation in the treatment of pancreatic cancer, recent advances in delivering short courses of high-dose stereotactic body radiation therapy, and how best to integrate this new modality in borderline and locally advanced disease.

Gastroesophageal Cancer

Ian Chau, MD, on Esophageal and Gastric Cancers: Systemic Agents and Options

Ian Chau, MD, of the Royal Marsden Hospital, discusses the continuum of care in esophageal and gastric cancers and the multiple active lines of treatment. Routine adoption of genomic testing may lead to further refinement of current treatment and more options in the future.

Hepatobiliary Cancer

Julien Edeline, MD, on Biliary Tract Cancer: Results of the PRODIGY 12-ACCORD 18 Trial

Julien Edeline, MD, of the Centre Eugène Marquis, discusses study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).

Advertisement

Advertisement




Advertisement